Updated from 11:57 a.m. EDTA Canadian company has started shipping a generic version of Bristol-Myers Squibb's (BMY - Get Report) biggest product, placing the New York drugmaker's sales, profit and dividend at risk of being substantially lowered.
Future Looks Grim for Bristol-Myers
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.